

Hepatotoxicity induced by greater celandine (*Chelidonium majus* L.): a review of the literature

F. PANTANO¹, G. MANNOCCHI¹, E. MARINELLI¹, S. GENTILI²,
S. GRAZIANO², F.P. BUSARDÒ¹, N.M. DI LUCA³

¹Unit of Forensic Toxicology (UoFT), Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy

²Drug Abuse and Doping Unit, Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy

³Department of Anatomical, Histological, Forensic and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy

Flaminia Pantano and Giulio Mannocchi contributed equally to the manuscript

Abstract. – The available literature assessing *Chelidonium majus* L. (CM) hepatotoxicity potential, and its risk to benefit assessment has been reviewed in this paper. Identification of significant scientific literature was performed via the following research databases: Cochrane Central, Google Scholar, EMBASE, Medline, Science Direct, Scopus, Web of Science, using the following keywords: “*Chelidonium majus*”, “greater celandine”, “Hepatotoxicity”, “Liver” “Injury”, “Toxicity” individually investigated and then again in association. CM named also greater celandine, swallow-wort, or bai-qu-cai (Chinese), has been used for a long time in traditional Chinese medicine and phytotherapy. Its extracts have been claimed to display a wide variety of biological activities: antimicrobial, anti-inflammatory, spasmolytic, antineoplastic, hepatoprotective, and analgesic. Moreover, herbal medicine suggests this plant have numerous additional effects which have not yet been scientifically evaluated, such as antitussive, diuretic, and eye-regenerative. However, despite its claimed hepatoprotective effects, several hepatotoxicity cases have been reported to be probably or highly probably connected with CM exposure, after their evaluation through liver-targeted causality assessment methods. CM hepatotoxicity has been defined as a distinct form of herb-induced liver injury (HILI), due to an idiosyncratic reaction of the metabolic type. This evidence has to be considered in relationship with the absence of considerable benefits of CM therapy. Therefore, the risk to benefit ratio of the use of herbal products containing greater celandine can actually be considered as negative.

Key Words:

Chelidonium majus L, Greater celandine, Hepatotoxicity, Liver, Injury, Toxicity.

Introduction

Chelidonium majus L. (CM), also known as greater celandine, is a plant of the family Papaveraceae, which grows wild in part of Asia, Central and Southern Europe, in the Azores and North America^{1,2}. It has been used for a long time in hepatobiliary disorders: gall bladder and digestive dysfunctions; dyspeptic complaints and spasms in phytotherapy and traditional medicine³. Currently, CM is widely marketed on the websites of natural products as a remedy against several medical complaints. The plant contains quaternary and tertiary benzo[c]phenanthridine alkaloids as major active components⁴. Recently, numerous hepatotoxicity reports have been suggested as linked with the use of herbal supplements containing CM^{5,6}. However, the causal relationship between CM intake and the occurrence of liver damage has not yet been fully established⁷. Animal studies showed that the prolonged administration of high doses of CM to rats did not determine liver damage, leading the authors to suggest to exclude an intrinsic plant toxicity⁸. Hence, it has been hypothesized that the harmfulness could have been due to pharmacological interaction⁹⁻¹². In this concern, the most severe reactions have been observed in subjects undergoing simultaneous treatment with CM and hormones (estrogens, thyroid hormones) and/or non-steroidal anti-inflammatory drugs (NSAIDs)¹³. The aim of this paper was to review the available literature assessing CM characteristics, risk to benefit ratio and its hepatotoxicity potential.

Materials and Methods

The selection of appropriate scientific articles was performed through the following research engines: Cochrane Central, Google Scholar, EMBASE, Medline, Science Direct, Scopus, Web of Science, up to October 2016 using the following keywords: “*Chelidonium majus*”, “greater celandine”, “Hepatotoxicity”, “Liver” “Injury”, “Toxicity”. The main keywords “*Chelidonium majus*” and “greater celandine” were searched individually and then in association with each of the others. The 244 and 57 sources initially found respectively with “*Chelidonium majus*” and “greater celandine”, were screened to exclude papers not suitable for the purpose of the review and duplicate sources. Only 43 papers [1, 4, 7-8, 10, 13-50] (25 research articles, 8 case reports, 9 reviews and 1 book) were included in the results. Moreover, a hand search was performed through the references of the identified articles.

Results

CM Mechanism of Action

A huge number of studies have been developed to assess CM efficacy in a large number of conditions, as this plant has been claimed to produce a wide variety of pharmacological effects¹. Medicinal properties of CM can be attributed to the isoquinoline alkaloids contained in the plant (root and aerial part). More than 27 components have been described and divided into three main groups: a) benzo[*c*]phenanthridines, among which there are two subgroups -quaternary (chelerythrine and sanguinarine) and -tertiary like chelidone; b) protopine and derivatives such as allocryptopine; c) protoberberines (berberine, coptisine)⁴. The plant contains flavonoids and phenolic acids as well¹⁴.

Anticancer activity of CM has been observed *in vitro* studies. The plant constituents determine cancer cell apoptosis and inhibition of mitosis¹⁵⁻¹⁷. Specifically, Ukrain, a semi-synthetic alkaloid derived from CM, is characterized by antitumor, antineoplastic and immunomodulatory properties, determining dose and time dependent cytotoxicity on cancer cell lines, among which those of breast cancer^{18,19}. Moreover, these effects have been observed after the administration of the whole extract of CM²⁰. Ukrain, showed therapeutic effects with low adverse reactions on various kinds of cancer (colorectal, breast, pancreatic,

bladder) and on Kaposi's sarcoma, as highlighted by human clinical studies²¹.

Also, CM action against inflammation has been studied in animal models, demonstrating that the methanol extract of this plant was able to inhibit the evolution of collagen-induced arthritis in mice, decreasing the synthesis of certain cytokines and modulating the amount of immune cells and immunoglobulins²². Kokoska and colleagues suggested that this herb could be one of the most active as an antimicrobial agent²³. Choleric activity has been studied on isolated perfused rat livers, on which alkaloid and phenolic fractions derived from CM and CM extract, determined a doubling of the amount of produced bile and a reduction of bile acid concentration, after 40 minutes²⁴. The choleric effect has also been studied in humans, through the administration of a hydroethanolic extract intragastrically in healthy patients and in subjects suffering from liver illness. Bile flow was found to be increased²⁵. Liver protection has been studied on rats, evaluating the defense from the toxicity due to carbon tetrachloride, through the administration of a whole extract of CM in ethanol^{26,27}. It has been shown that the previous treatment with CM was able to reduce the number of necrotic cells, the value of transaminases, bilirubin, and the fibrotic changes due to carbon tetrachloride exposure. Also, the hepatocarcinogenesis caused by p-dimethylaminoazobenzene was found to be antagonized by CM in mice²⁸. Anti-ulcerogenic and gastroprotective effects of CM extract have been evaluated on gastric ulcers induced by indomethacin in rats. CM showed an action against the development of ulcers, enhancing the release of prostaglandin E2 and decreasing leukotrienes²⁹, and producing an antispasmodic and analgesic activity as well. The analgesic effect determined by its alkaloids was similar to that of morphine. The CM extracts produced a relaxing and spasmolytic action on the abdominal and gastrointestinal muscles in animal models, being able to reduce pain^{30,32}. This effect was observed also in human clinical studies³³.

CM Hepatotoxicity

Animal Studies

Some studies on animal models have been developed in order to assess the defensive properties of CM constituents or their ability to enhance the toxicity of other molecules. The protective potential of chelidone, the major active compo-

ment of *Chelidonium majus*, and of its poly lactide-co-glycolide (PLGA) poly encapsulated nano-form (nano-chelidonine), has been evaluated in the oxidative stress and hepatic toxicity induced by cadmium chloride (CdCl_2) in mice³⁴. The study results showed that the exposure to CdCl_2 for 30 days (twice a week at the following dosage: 1.0 mg/kg body weight i.p.) caused oxidative stress through lipid peroxidation and accumulation of reactive oxygen species (ROS). The administration of nano-chelidonine after CdCl_2 exposure markedly diminished lipid peroxidation and oxidative stress and restored GSH (glutathione) levels. Therefore, nano-chelidonine was suggested as a protective agent, in mice, against cadmium toxicity. Also, the ability of CM to enhance the hepatic effects of acetaminophen at a sub-toxic dose was evaluated in rats⁷. If administered alone, CM did not modify liver parameters in male rats while in female animals a rise of fibrinogen levels was observed. No changes in hepatic histomorphology were noticed in both sexes. Liver alterations were observed after the administration of sub-toxic doses of acetaminophen, while the co-administration of CM did not enhance hepatotoxic effects. Additionally, the anti-tumor properties of CM and its modulation of enzyme activity in the liver have been studied administering a homeopathic extract (in micro doses Ch-30 and Ch-200) of CM to mice, during hepatocarcinogenesis induced by p-DAB (p-dimethylaminoazobenzene) compared to control groups³⁵. All mice that were administered p-DAB developed liver tumors. Approximately the 40% of the animals in which p-DAB was administered in association with Chelidonium, did not develop liver tumors. Chelidonium homeopathic medicine showed an anti-tumor effect and an anti-genotoxic activity and favorably modulated the effects of certain enzyme markers. Moreover, the inhibition potency of CM alkaloids on several enzymes was tested in animal studies. Chelidonine, berberine, sanguinarine, and "Ukrain" (a semisynthetic drug derived from CM) displayed an irreversible inhibition of serotonin and tyramine oxidative deamination reaction, in rat livers mitochondrial monoamine oxidase (MAO)³⁶. However, the same metabolic pathway was not blocked for the substrate benzylamine. This finding suggests that mainly oxidative deamination performed by MAO form A is blocked by CM alkaloids. Ukrain and chelidonine showed the strongest inhibition potency, while sanguinarine and berberine exhibited a weaker action³⁷. Similarly, the inhibition potential of CM alkaloids,

was studied in liver mitochondria of male albino mice⁴. The molecules showing greater inhibition strength in mitochondrial respiration were those containing a positive charge, for the presence in their structure of a quaternary nitrogen atom: chelerythrine, sanguinarine, berberine and coptisine. The uncharged CM constituents underwent more troubles in passing through the mitochondrial membrane. Berberine, was the most biologically active alkaloid tested, and for this reason, it should display the highest toxicity. Moreover, the effects of chelidonine, coptisine, chelerythrine, and sanguinarine were studied on oxidative phosphorylation and calcium accumulation in rat liver mitochondria³⁸. Chelerythrine and sanguinarine determined a block of the absorption and the accumulation of calcium cations and repressed oxidative phosphorylation, while chelidonine did not influence the studied parameters. The effects observed on mitochondria are directly connected to DNA intercalating properties, as sanguinarine and chelerythrine are strong intercalators, while chelidonine is not. Finally, after oral administration of CM on Wistar rats for two or four weeks, at the following dosage: 1.5-3 g/(kg day) (this amount should be considered 50-100 times higher than that generally consumed by humans), no substantial change was noticed in animals, regarding to: body weight, food intake, enzyme activities and liver histomorphology. Nevertheless, a mild but significant reduction of GSH levels, as well as superoxide dismutase (SOD) activity was observed. Therefore, these mild alterations suggest particular caution in administering CM in conditions characterized by an impairment of liver function⁸.

Human Hepatotoxicity Reports

The liver damage due to herbal remedies is also named: herb-induced liver injury (HILI). The latter represents a rare occurrence that follows the exposure in a small amount of susceptible individuals³⁹⁻⁴¹. HILI features are comparable to those of drug-induced liver injury (DILI). While performing causality assessment, it is of primary importance to choose the proper evaluation method. Teschke and Danan stressed the concept that causality assessment in HILI suspected cases should be performed through the Council for International Organizations of Medical Sciences scale (CIOMS), also known as Roussel Uclaf Causality Assessment Method (RUCAM) which is an instrument validated for hepatotoxicity and specific for the liver⁴².

Liver damage due to CM intake in humans has been mainly supported by case reports and

reviews that evaluated the cases reported in scientific papers and spontaneous signaled adverse reactions. The onset of haemolytic anaemia due to the oral ingestion of CM extract was firstly observed in 1990 and was characterized by intravascular haemolysis, thrombocytopenia, renal failure and liver cytolysis⁴³. The patient underwent treatment with steroids, blood components, transfusion and with haemodialysis twice. The 12th-day complete resolution of the clinical features was observed. Similarly, a 42-year-old woman was admitted to the hospital because of the reappearance of acute hepatitis of uncertain origin⁴⁴. Her past clinical history was characterized by alanine transaminase (ALT) elevation (concentration of 755 U/l), preceded by the intake of herbal remedies as an alternative medication, including common (or lesser) celandine. ALT maximum values during the hospitalization were 350 U/l. All other possible causes of hepatitis, such as viral infection, metabolic diseases, and autoimmune aetiology were excluded. Liver biopsy showed an acute necrotizing hepatitis. Treatment was performed mainly through the avoidance of re-exposure and liver enzymes returned normal. Concordantly, ten cases of acute hepatitis connected with the intake of CM preparations were noticed from 1997 until 1999 in Germany¹³. The evolution of liver impairment in these patients was mild to severe. In half of the cases, important cholestasis was detected, but was not followed by liver failure. Other potential sources of liver damage such as secondary biliary, alcoholic damage, viral hepatitis, hereditary and autoimmune conditions were excluded performing imaging procedures, laboratory tests and liver biopsies. These last were compatible with damage induced by drugs. The discontinuation of CM intake determined rapid recovery in patients and the level of liver enzymes returned normal in 2-6 months. Unintentional re-exposure determined recurrence of hepatitis in one patient, this fact, is the most appropriate criterion for HILI causality assessment⁴⁵. In conclusion, a great percentage of unsolved cases of hepatitis could be related to CM. Moreover, the manifestation of jaundice related to acute hepatitis was observed in a 42-year-old woman, several weeks after the consumption a herbal remedy containing CM and curcuma root, which she took for a skin illness⁴⁶. In accordance with the cases reported above, clinical conditions improved rapidly after the discontinuation of the herbal product

and the hepatic functions were found to be normal within two months. Two cases of acute liver damage connected with the use of CM where also reported in 2003⁴⁷. In both patients, other culprits of acute liver injury were excluded, in order to assess causality. A recurrence of cholestatic hepatitis after CM re-exposure occurred in one patient. The two patients recovered fully, but the authors highlight the fact that the authorization of CM administration should be reconsidered, as actually there is a lack of therapeutic benefits connected with this drug. Another case regards a 58-year-old man admitted with acute cholestatic hepatitis after the use of a CM preparation⁴⁸. Histopathology showed a picture of drug-induced hepatitis however after discontinuation of the herbal product the patient recovered fully. A further case of liver damage was described in 2008, involving a woman admitted to the hospital for asthenia, nausea, anorexia and with deranged liver enzymes⁴⁹. She was found to have used a *Lycopodium similiaplex* preparation (containing *Lycopodium serratum* and *Chelidonium majus*) for 8 weeks before the onset of symptoms. Liver biopsy was suggestive of a hypersensitivity reaction and concordantly with the other reports she fully recovered. Teschke et al¹⁰ evaluated the connection between CM intake and hepatotoxicity in 21 published case reports, using a causality evaluation method specific for the liver, as a multitude of confounding variables might have misled causality. For this reason, all 21 cases were examined through the CIOMS scale, which considers: risk factors, the latency period, comedication and other alternative causes, the trend of ALT after drug withdrawal. The results showed a high probability of causality in two cases out of 21. Probable in six cases. Lower causality levels were found in the remaining cases in which the causality was excluded for three patients and recognized as possible in 10 cases. Regarding the 8 probable events, hepatotoxicity due to CM embodies an idiosyncratic reaction of the metabolic kind, while immunologic or mandatory hepatotoxic characteristics are missing. Therefore, an accurate search and identification of confounding variables should be performed while evaluating the cases, but there is striking evidence for HILI due to GC in the cases analyzed by the authors. Moreover, the same author evaluated 22 spontaneous cases from Germany attributing to 8 events, a highly probable or probable causality assessment, with a predominance for the female

gender⁵⁰. All patients recovered. Taken together, the above-reported case reports actually support the hepatotoxic potential of CM preparations.

Conclusions

An abundant number of herbal remedies has been suggested to be linked with the risk of liver damage, this side effect, as well as others, must be clearly underlined, in the light of an increase of popularity of herbal preparations⁵¹. Moreover, the clinical effectiveness of these remedies is frequently only supposed and does not seem to counterbalance the potential risks. Although important evidence of hepatotoxicity in animal studies is still not well defined, CM extracts and constituents displayed alterations and inhibition of liver metabolism suggestive for hepatotoxic potential. Numerous reports have been published about hepatotoxicity cases following CM intake, and several of them have been reported to be connected with CM exposure with probability or high probability. Liver histology, when available, showed: liver cell necrosis (single or confluent), inflammation and more seldom cholestasis and fibrosis⁵². CM hepatotoxicity has been defined as a distinct form of HILI, due to an idiosyncratic reaction of the metabolic type. This fact has to be evaluated in relationship with the lack of substantial benefits due to the therapy with CM. For these reasons, currently, the risk to benefit ratio of the use of herbal products containing CM can be considered as negative, although the described hepatotoxicity has generally manifested a benign course with the recovery of the patients after discontinuation of the intake.

Authors' contributions

All the authors made substantial contributions to conception and design of the manuscript; GM, FP and SG performed the literature search and NML, FPB and SG revised it. All the authors have been involved in drafting the manuscript and revising it critically for important intellectual content and all of them have given final approval to the version to be published.

Acknowledgements

The authors thank Michele Sciotti for technical assistance in manuscript preparation.

Conflict of interest

The authors declare no conflicts of interest.

References

- 1) GILCA M, GAMAN L, PANAIT E, STOIAN I, ATANASIU V. Chelidonium majus--an integrative review: traditional knowledge versus modern findings. *Forsch Komplementmed* 2010; 17: 241-248.
- 2) KADAN G, GÖZLER T, SHAMMA M. (-)-Turkiyenine, a new alkaloid from Chelidonium majus. *J Nat Prod* 1990; 53: 531-532.
- 3) BARNES J, ANDERSON LA, PHILLIPSON JD. Celandine, greater. *Herbal medicines*. Pharmaceutical Press, 2007.
- 4) BARRETO MC, PINTO RE, ARRABACA JD, PAVÃO ML. Inhibition of mouse liver respiration by Chelidonium majus isoquinoline alkaloids. *Toxicology Letters* 2003; 146: 37-47.
- 5) TARANTINO G, PEZZULLO MG, DI MINNO MN, MILONE F, PEZZULLO LS, MILONE M, CAPONE D. Drug-induced liver injury due to "natural products" used for weight loss: a case report. *World J Gastroenterol* 2009; 15: 2414-2417.
- 6) TESCHKE R, GLASS X, SCHULZE J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. *Regul Toxicol Pharmacol* 2011; 61: 282-291.
- 7) MAZZANTI G, DI SOTTO A, DI GIACOMO S, DURAZZI F, MARIANI P, NICOLETTI M, MAMMOLA CL, VITALONE A. CHELIDONIUM MAJUS L. does not potentiate the hepatic effect of acetaminophen. *Exp Toxicol Pathol* 2013; 65: 1117-1120.
- 8) MAZZANTI G, DI SOTTO A, FRANCHITTO A, MAMMOLA CL, MARIANI P, MASTRANGELO S, MENNITI-IPPOLITO F, VITALONE A. Chelidonium majus is not hepatotoxic in Wistar rats, in a 4 weeks feeding experiment. *J Ethnopharmacol* 2009; 126: 518-524.
- 9) MORO PA, CASSETTI F, GIUGLIANO G, FALCE MT, MAZZANTI G, MENNITI-IPPOLITO F, RASCETTI R, SANTUCCIO C. Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. *J Ethnopharmacol* 2009; 124: 328-332.
- 10) TESCHKE R, GLASS X, SCHULZE J, EICKHOFF A. Suspected Greater Celandine hepatotoxicity: liver-specific causality evaluation of published case reports from Europe. *Eur J Gastroenterol Hepatol* 2012; 24: 270-280.
- 11) WILLIAMSON EM. Drug interactions between herbal and prescription medicines. *Drug Saf* 2003; 26: 1075-1092.
- 12) OLESEN C, HARBIG P, BARAT I, DAMSGAARD EM. Absence of 'over-the-counter' medicinal products in on-line prescription records: a risk factor of overlooking interactions in the elderly. *Pharmacoepidemiol Drug Saf* 2013; 22: 145-150.
- 13) BENNINGER J, SCHNEIDER HT, SCHUPPAN D, KIRCHNER T, HAHN EG. Acute hepatitis induced by greater celandine (Chelidonium majus). *Gastroenterology* 1999; 117: 1234-1237.

- 14) COLOMBO ML, BOSISIO E. Pharmacological activities of *Chelidonium majus* L. (Papaveraceae). *Pharmacol Res* 1996; 33: 127-134.
- 15) NOUREINI SK, WINK M. Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonium. *World J Gastroenterol* 2009; 15: 3603-3610.
- 16) HABERMEHL D, KAMMERER B, HANDRICK R, ELDH T, GRUBER C, CORDES N, DANIEL PT, PLASSWILM L, BAMBERG M, BELKA C, JENDROSSEK V. Proapoptotic activity of Ukrain is based on *Chelidonium majus* L. alkaloids and mediated via a mitochondrial death pathway. *BMC Cancer* 2006; 6: 14.
- 17) PHILCHENKOV A, KAMINSKY V, ZAVELEVICH M, STOIKA R. Apoptogenic activity of two benzophenanthridine alkaloids from *Chelidonium majus* L. does not correlate with their DNA damaging effects. *Toxicol In Vitro* 2008; 22: 287-295.
- 18) BOZEMAN EN, SRIVATSAN S, MOHAMMADI H, DANIELS D, SHASHIDHARAMURTHY R, SELVARAJ P. Ukrain, a plant derived semi-synthetic compound, exerts antitumor effects against murine and human breast cancer and induce protective antitumor immunity in mice. *Exp Oncol* 2012; 34: 340-347.
- 19) JAGIELLO-WÓJTOWICZ E, KLEINROK Z, URBANSKA EM. Ukrain (NSC-631570) in experimental and clinical studies: a review. *Drugs Exp Clin Res* 1998; 24: 213-219.
- 20) DELJANIN M, NIKOLIC M, BASKIC D, TODOROVIC D, DJURDJEVIC P, ZARIC M, STANKOVIC M, TODOROVIC M, AVRAMOVIĆ D, POPOVIC S. *Chelidonium majus* crude extract inhibits migration and induces cell cycle arrest and apoptosis in tumor cell lines. *J Ethnopharmacol* 2016; 190: 362-371.
- 21) ERNST E, SCHMIDT K. Ukrain – a new cancer cure? A systematic review of randomised clinical trials. *BMC Cancer* 2005; 5: 69.
- 22) LEE YC, KIM SH, ROH SS, CHOI HY, SEO YB. Suppressive effects of *Chelidonium majus* methanol extract in knee joint, regional lymph nodes, and spleen on collagen-induced arthritis in mice. *J Ethnopharmacol* 2007; 112: 40-48.
- 23) KOKOSKA L, POLENSKY Z, RADA V, NEPOVIM A, VANEK T. Screening of some Siberian medicinal plants for antimicrobial activity. *J Ethnopharmacol* 2002; 82: 51-53.
- 24) VAHLENSIECK U, HAHN R, WINTERHOFF H, GUMBINGER HG, NAHRSTEDT A, KEMPER FH. The effect of *Chelidonium majus* herb extract on choleresis in the isolated perfused rat liver. *Planta Med* 1995; 61: 267-271.
- 25) BAUMANN JC. Effect of chelidonium, curcuma, absinth and *Carduus marianus* on the bile and pancreatic secretion in liver diseases. *Med Monatschr* 1975; 29: 173-180.
- 26) MITRA S, GOLE M, SAMAJDAR K, SUR RK, CHAKRABORTY BN. Antihepatotoxic activity of *Chelidonium majus*. *Int J Pharmacognosy* 1992; 30: 125-128.
- 27) MITRA S, SUR RK, ROY A, MUKHERJEE AS. Effect of *Chelidonium majus* L. on experimental hepatic tissue injury. *Phytother Res* 1996; 10: 354-356.
- 28) BISWAS J, BHATTACHARJEE N, KHUDA-BUKHSH AR. Efficacy of a plant extract (*Chelidonium majus* L.) in combating induced hepatocarcinogenesis in mice. *Food Chem Toxicol* 2008; 46: 1474-1487.
- 29) KHAYYAL MT, EL-GHAZALY MA, KENAWY SA, SEIFEL-NASR M, MAHRAN LG, KAFABI YA, OKPANYI SN. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. *Arzneimittelforschung* 2001; 51: 545-553.
- 30) HUANG CK. *The Pharmacology of Chinese Herbs*. CRC Press LLC, 1999.
- 31) BOEGGE SC, KESPER S, VERSPOHL EJ, NAHRSTEDT A. Reduction of Ach-induced contraction of rat isolated ileum by coptisine, (+) caffeoylmalic acid, *Chelidonium majus*, and *Corydalis lutea* extracts. *Planta Med* 1996; 62: 173-174.
- 32) HILLER KO, GHORBANI M, SCHILCHER H. Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and *Chelidonium majus* extracts on isolated guinea-pig ileum. *Planta Med* 1998; 64: 758-760.
- 33) NIEDERAU C, GÖPFERT E. The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study. *Med Klin (Munich)* 1999; 94: 425-430.
- 34) PAUL A, DAS J, DAS S, SAMADDER A, KHUDA-BUKHSH AR. Poly (lactide-co-glycolide) nano-encapsulation of chelidonine, an active bioingredient of greater celandine (*Chelidonium majus*), enhances its ameliorative potential against cadmium induced oxidative stress and hepatic injury in mice. *Environ Toxicol Pharmacol* 2013; 36: 937-947.
- 35) BISWAS SJ, KHUDA-BUKHSH AR. Effect of a homeopathic drug, *Chelidonium*, in amelioration of p-DAB induced hepatocarcinogenesis in mice. *BMC Complement Altern Med* 2002; 10: 2-4.
- 36) IAGODINA OV, NIKOL'SKAIA EB, FADDEEVA MD. Inhibition of liver mitochondrial monoamine oxidase activity by alkaloids isolated from *Chelidonium* and *Macleaya* and by their derivative drugs. *Tsitologiya* 2003; 45: 1032-1037.
- 37) KUZNETSOVA LP, SOCHILINA EE, FADDEEVA MD, IAGODINA OV. Effect of some isoquinoline alkaloids on enzymatic activity of acetylcholinesterase and monoamine oxidase. *Ukr Biokhim Zh* 1999; 77: 147-153.
- 38) KAMINS'KYĎ VO, KRYV'IAK NV, LUTSYK MD, STOĎKA RS. Effect of alkaloids from celandine on calcium accumulation and oxidative phosphorylation in mitochondria depending on their DNA intercalating properties. *Ukr Biokhim Zh* 1999; 78: 73-78.
- 39) TESCHKE R, FRENZEL C, GLASS X, SCHULZE J, EICKHOFF A. Herbal hepatotoxicity: a critical review. *Br J Clin Pharmacol* 2013; 75: 630-636.
- 40) TESCHKE R, FRENZEL C, SCHULZE J, EICKHOFF A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. *World J Gastroenterol* 2013; 19: 2864-2882.
- 41) TESCHKE R, WOLFF A. Kava hepatotoxicity: regulatory data selection and causality assessment. *Dig Liver Dis* 2009; 41: 891-901.

- 42) DANAN G, TESCHKE R. RUCAM in drug and herb induced liver injury: the update. *Int J Mol Sci* 2015; 17: 1.
- 43) PINTO GARCÍA V, VICENTE PR, BAREZ A, SOTO I, CANDAS MA, COMA A. Hemolytic anemia induced by Chelidonium majus. Clinical case. *Sangre (Barc)* 1990; 35: 401-403.
- 44) STRAHL S, EHRET V, DAHM HH, MAIER KP. Necrotizing hepatitis after taking herbal medication (extracts of kava or of common or lesser celandine). *Dtsch Med Wochenschr* 1998; 123: 1410-1414.
- 45) TESCHKE R, GENTHNER A, WOLFF A, FRENZEL C, SCHULZE J, EICKHOFF A. Herbal hepatotoxicity: analysis of cases with initially reported positive re-exposure tests. *Dig Liver Dis* 2014; 46: 264-269.
- 46) CRIJNS AP, DE SMET PA, VAN DEN HEUVEL M, SCHOT BW, HAAGSMA EB. Acute hepatitis after use of a herbal preparation with greater celandine (*Chelidonium majus*). *Ned Tijdschr Geneesk* 2002; 146: 124-128.
- 47) STICKEL F, PÖSCHL G, SEITZ HK, WALDHERR R, HAHN EG, SCHUPPAN D. Acute hepatitis induced by Greater Celandine (*Chelidonium majus*). *Scand Gastroenterol* 2003; 38: 565-568.
- 48) RIFAI K, FLEMMING P, MANN S, TRAUTWEIN C. Severe drug hepatitis caused by *Chelidonium majus*. *Internist* 2006; 47: 749-751.
- 49) CONTI E, DE CHECCHI G, MENCARELLI R, PINATO S, ROVERE P. *Lycopodium similiaplex*-induced acute hepatitis: a case report. *Eur J Gastroenterol Hepatol* 2008; 20: 469-471.
- 50) TESCHKE R, GLASS X, SCHULZE J. Herbal hepatotoxicity by Greater Celandine (*Chelidonium majus*): causality assessment of 22 spontaneous reports. *Regul Toxicol Pharmacol* 2011; 61: 282-291.
- 51) VALENTE G, SANGES M, CAMPIONE S, BELLEVICINE C, DE FRANCHIS G, SOLLAZZO R, MATTERA D, CIMINO L, VECCHIONE R, D'ARIENZO A. Herbal hepatotoxicity: a case of difficult interpretation. *Eur Rev Med Pharmacol Sci* 2010; 14: 865-870.
- 52) TESCHKE R, FRENZEL C, GLASS X, SCHULZE J, EICKHOFF A. Greater Celandine hepatotoxicity: a clinical review. *Ann Hepatol* 2012; 11: 838-848.